These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30076105)

  • 1. Modelling norovirus transmission and vaccination.
    Gaythorpe KAM; Trotter CL; Conlan AJK
    Vaccine; 2018 Sep; 36(37):5565-5571. PubMed ID: 30076105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of norovirus vaccination in children in Peru.
    Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH
    Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic challenges in norovirus vaccine development.
    Hallowell BD; Parashar UD; Hall AJ
    Hum Vaccin Immunother; 2019; 15(6):1279-1283. PubMed ID: 30481104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential economic value of a human norovirus vaccine for the United States.
    Bartsch SM; Lopman BA; Hall AJ; Parashar UD; Lee BY
    Vaccine; 2012 Nov; 30(49):7097-104. PubMed ID: 23026689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the epidemiological impact of rotavirus vaccination in Germany--a Bayesian approach.
    Weidemann F; Dehnert M; Koch J; Wichmann O; Höhle M
    Vaccine; 2014 Sep; 32(40):5250-7. PubMed ID: 25045820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
    Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of immunity to norovirus gastroenteritis.
    Simmons K; Gambhir M; Leon J; Lopman B
    Emerg Infect Dis; 2013 Aug; 19(8):1260-7. PubMed ID: 23876612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control.
    Lopman BA; Steele D; Kirkwood CD; Parashar UD
    PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norovirus Vaccine: Priorities for Future Research and Development.
    Esposito S; Principi N
    Front Immunol; 2020; 11():1383. PubMed ID: 32733458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-assessing the total burden of norovirus circulating in the United Kingdom population.
    Harris JP; Iturriza-Gomara M; O'Brien SJ
    Vaccine; 2017 Feb; 35(6):853-855. PubMed ID: 28094075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Depth Breadth Analyses of Human Blockade Responses to Norovirus and Response to Vaccination.
    Haynes J; Perry V; Benson E; Meeks A; Watts G; Watkins H; Braun R
    Viruses; 2019 Apr; 11(5):. PubMed ID: 31035476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on norovirus vaccine research: public health considerations and future directions.
    Mattison CP; Cardemil CV; Hall AJ
    Expert Rev Vaccines; 2018 Sep; 17(9):773-784. PubMed ID: 30092671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Norovirus (infants/children)].
    Onishi S
    Nihon Rinsho; 2012 Aug; 70(8):1366-70. PubMed ID: 22894074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profile of children with norovirus disease in rotavirus vaccine era.
    Wikswo ME; Desai R; Edwards KM; Staat MA; Szilagyi PG; Weinberg GA; Curns AT; Lopman B; Vinjé J; Parashar UD; Payne DC; Hall AJ
    Emerg Infect Dis; 2013 Oct; 19(10):1691-3. PubMed ID: 24047618
    [No Abstract]   [Full Text] [Related]  

  • 17. Norovirus transmission dynamics: a modelling review.
    Gaythorpe KAM; Trotter CL; Lopman B; Steele M; Conlan AJK
    Epidemiol Infect; 2018 Jan; 146(2):147-158. PubMed ID: 29268812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.
    Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D;
    Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options.
    Steele MK; Remais JV; Gambhir M; Glasser JW; Handel A; Parashar UD; Lopman BA
    Epidemics; 2016 Dec; 17():42-49. PubMed ID: 27821278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global age distribution of pediatric norovirus cases.
    Shioda K; Kambhampati A; Hall AJ; Lopman BA
    Vaccine; 2015 Aug; 33(33):4065-8. PubMed ID: 26051514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.